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Purpose: We determined the indication, outcome and risk factors of single and multiple hema-
topoietic stem cell transplantation(s) (HSCT) in children and adolescents mostly with advanced 
disease.  
Methods: Forty-one out of 483 patients (8.5%; median age 9 years) diagnosed at the University 
of Leipzig with haematological and oncological diseases required HSCT from 1999 to 2011.  
Results: Patients had overall survival (OS) of 63±10% and 63±16%, event-free survival (EFS) 
of 57±10% and 42±16%, relapse incidence (RI) of 39±10% and 44±18% and non-relapse mor-
tality (NRM) of 4±4% and 13±9% at 10-years after one or more HSCT for allogeneic and autolo-
gous HSCT, respectively. One patient in complete remission (CR)1 and five with advanced dis-
ease received two HSCT. Four of the six patients maintained/achieved CR for a median of 13 
months. Three died of progression and one of NRM. Two patients had a third HSCT and one 
survived in CR +231 days after HSCT. Risk factors for OS and EFS were disease stage at 
HSCT and EBMT risk-score. Center (paediatric or JACIE accredited paediatric/adult) was not a 
determinant for survival.  
Conclusion: Paediatric single and multiple HSCT are important curative approaches for high-




The idea of replacing a diseased or tumour cell contaminated bone marrow with a 
healthy marrow was developed in the first part of the 19th century. However, the suc-
cessful engraftment of donor hematopoietic cells in a different host required many dec-
ades of work and unsuccessful attempts. In the late fifties, transient engraftment of do-
nor cells was first demonstrated by blood group changes1. None of the refractory pa-
tients survived, but the proof of concept was demonstrated. More than 200 transplants 
were performed in the following years with a success rate of below 1%.2 This led to a 
decrease in transplant activity to <10 transplantations/year in 1962. Finally, after pro-
gress in experimental transplantation and after understanding the basics of hematopoi-
etic stem cell transplantation (HSCT) (including immunological barriers revealed by HLA 
skin–grafting experiments) the first successful allogeneic transplants were performed in 
twins. Further interdisciplinary work, progress in drug development and exchange of 
experiences through scientific societies gradually led to survival in patients with other-
wise incurable diseases. Since these early days, constant improvements in outcome 
have been observed, establishing HSCT as the only curative treatment for many malig-
nant haematological diseases and for bone marrow failures worldwide. At the end of the 
70s the first patients with lymphoma were transplanted after high dose therapy and au-
tologous stem cell rescue (first autologous HSCT). In contrast to autologous HSCT, 
where the only mechanism is ultrahigh radio chemotherapy and stem cells are given to 
rescue the patient from irreversible marrow damage, two mechanisms are involved in 
allogeneic HSCT: the ultrahigh chemo/radiotherapy and an immunological destruction of 
tumour cells resulting from a graft-versus-tumour (GvT) reaction. GvT was first de-
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scribed in patients with graft-versus-host disease (GvHD), who showed lower relapse 
incidence than patients without GvHD, and was underestimated for a long period of 
time. The importance of GvT was realized only after the successful infusion of donor 
lymphocytes (DLI) in patients with relapse after HSCT by the end of the nineties.3 This 
led in the late nineties to the development of strategies that reduce the intensity of con-
ditioning regimens and use GvT as the primary mechanism to treat malignant diseases 
in elderly patients and in patients with comorbidities. In addition to malignant diseases, 
HSCT was already used in the 80s to treat non-malignant genetic diseases such thalas-
semia and sickle cell anaemia. The indications for HSCT increased steadily and the 
shortage of related donors became a limiting factor. As a consequence, unrelated donor 
HSCT was introduced in 1980 and led to a further increase in the worldwide HSCT ac-
tivity. The use of peripheral blood stem cells rather than bone marrow derived cells for 
autologous and later also for allogeneic HSCT was made possible by the availability of 
hematopoietic growth factor for mobilizing stem cells from the bone marrow to peripher-
al blood. Despite unrelated donor registries worldwide, donors were still not found for 
every patient. This led to the development of alternate transplants using cord blood as 
the stem cell source, firstly in children4 and later for mismatched and haploidentical re-
lated HSCT5. The success of and indications for HSCT have increased steadily over the 
years with the one millionth HSCT being performed in 2012.6 Experience has been 
gained mainly in adult patients, while indication and experience in children and adoles-
cents has remained limited due partly to the high success rate of intense chemothera-
pies and better outcome of malignant diseases in younger patients. 
In recent decades, significant improvements have been made especially in defining risk 
factors7 and in treating complications after HSCT. These resulted in a significant de-
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crease of transplant related mortality (TRM) down to 26% TRM.8 The main problems 
associated with HSCT were graft rejection, bacterial, fungal and viral infection, GvHD 
and in rare occasions veno-occlusive disease (VOD). While for the first transplants graft 
rejection was the most frequent problem,2 the understanding of the host-versus-graft 
reaction was essential to decrease this complication to the current figure of below 5% 
after conventional HSCT. For a long time it was believed that the destruction of the host 
immune system and the creation of sufficient space for the bone marrow to host donor-
derived hematopoiesis were essential and that this is directly dependent on the intensity 
of the preparative regimen (conditioning). Later on, rather than the intensity of the condi-
tioning, the specific destruction of immunocompetent recipient T-cells, the use of the 
graft-versus-host reaction and prophylactic GvHD treatment were adopted to ensure 
engraftment of allogeneic stem cells. This opened up the possibility of using less mye-
loablative conditioning (so called reduced intensity conditioning HSCT) to allow the use 
of HSCT in elderly patients and in patients with comorbidities. Today almost 30% of 
HSCT are performed with different degrees of reduced intensity conditioning, relying on 
the GvT effect as an important antitumor mechanism to treat patients with incurable dis-
ease.   
Infections 
Considerable improvements have been made in reducing the infection rate by improving 
supportive therapy. Patients were isolated to prevent bacterial and fungal infections, but 
also new therapies have become available to treat bacterial infections and viral infec-
tions (Herpes) or reactivations. Prophylactic antibiotics to prevent pneumocystis Carinii 
and Toxoplasmosis for patients at risk are considered routine today. Determination of 
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CMV transcripts post-transplant is considered standard to detect reactivation or disease 
and enable the early start of therapy.  
 
Veno-occlusive disease (VOD) 
Veno-occlusive disease is an early complication leading to sinuosoidal vein obstructions 
in the liver. The complication, especially frequent in children, may have mild or severe 
course and may lead in its more severe form to multiorgan failure (MOF) with severe 
damage to organs and requirement of dialysis or ventilation. Severe VOD results in a 
high mortality rate. These days, mortality rate can be reduced considerably using De-
fibrotide early in the disease and data on prophylaxis are also available.9,10  A particular-
ly high incidence is observed in children with osteopetrosis and in adults with a history 
of liver disease, extensive chemotherapy treatment history and treatment with CD33 
antibody. 
Graft rejection   
Graft rejection was the major complication in the early transplant era, where more than 
50% of the patients rejected their graft with only transient engraftment. An understand-
ing of the mechanisms involved in engraftment led to a substantial decrease in graft 
rejection rate to the current frequency of below 5% of HSCT. Major determinants are 
sensitization with donor cells before HSCT, the immune competence of the recipient, 
the degree of matching between donor and recipient and the composition of the graft. 
On the patient side, sufficient conditioning or specific depletion of immune competent 
recipient cells is needed pre-transplant. The minimal amount of donor cells in the graft 
has been defined and also post-transplant immune suppression has been recognized 
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as important factor in avoiding rejection, especially in patients treated with reduced in-
tensity conditioning. 
Graft-versus Host Disease (GvHD) 
While graft rejection is an immune mediated reaction of recipient against donor cells, 
the major complication remains a reaction of donor against recipient cells (GvHD) that 
manifests primarily in the liver, skin and gut, although other organs like lung may be in-
volved as well. The reaction may have different degrees of severity from 0 to IV and 
may contribute to mortality despite additional immune suppressive therapy. Two distinct 
patterns of GvHD are observed: the acute and the chronic. The acute in its more severe 
form may lead to liver failure, to severe diarrhea and to skin alterations ranging from 
erythema to diseases resembling Lyell syndrome. The reaction is caused despite identi-
ty of the major Histocompatibility Antigens (HLA identity) by donor T-cells recognizing 
targets on recipient cells called minor Histocompatibility antigens (MiHA). Cytokines al-
so play an important role in the induction and persistence of the disease, which increas-
es with the degree of incompatibility between donor and recipients and with recipient 
age. In order to avoid GvHD, prophylaxis is started pre-transplant to all patients except 
in syngeneic HSCT and usually discontinued in the absence of GvHD six months after 
HSCT. While in the beginning only methotrexate (Mtx) was given, today a combination 
of cyclosporine and Mtx is considered standard. Other calcineurin antagonists (e.g. tac-
rolimus), m-tor inhibitors (e.g. sirolimus) or mycophenolate mofetil might be used as well 
either in combinations or as monotherapy. Despite prophylaxis, GvHD grade I is still 
observed in 30% of the patients without any need for additional immunosuppressive 
therapy. Approx. 30% have GvHD grade II and higher requiring steroids as first line 
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GvHD therapy. The majority will respond to steroids and for non-responding patients 
ATG, ECP and other immune suppressive manipulations are available. The death rate 
in GvHD grade III-IV is very high, despite treatment. While acute GvHD usually devel-
ops within 100 days of transplant, chronic GvHD is seen after day 100 and resembles 
scleroderma and may appear de novo or after acute GvHD. Patients with grade I GvHD 
have a considerable GvT effect and therefore have a better prognosis than GvHD grade 
0  and GvHD >II. 
Non-relapse mortality (NRM) 
NRM has decreased over recent decades as a consequence of better supportive thera-
py, molecular typing for unrelated recipient and donor pairs, prophylactic anti-infective 
treatments and decreases in severe GvHD.7 The use of reduced intensity conditioning 
and decrease in NRM has enabled HSCT even in elderly patients and in younger pa-
tients with comorbidities and made multiple HSCT in adults possible. In children, data 
on multiple HSCT are scarce or missing.   
Relapse of the underling disease 
HSCT has the most potent antitumor activity of any therapy including molecular therapy 
with small molecules. Relapse depends very much on the stage of the disease at HSCT 
with patients in remission relapsing less frequently than patients who are treated in re-
lapse or with advanced disease (e.g. blast crisis in chronic myeloid leukemia). While 
excellent progress has been made in decreasing NRM in recent years, disease relapse 
remains a major problem. Relapse risk depends upon the underling disease (e.g. cyto-
genetic risk in AML) and duration of the disease (CML). Other factors affecting relapse 
rate include transplant related features like T-cell depletion and duration of immunosup-
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pression. Relapse occurs usually within two years after HSCT. As a consequence, pa-
tients are considered to be cured two years after allogeneic HSCT. Treatment of relapse 
involves chemotherapy, donor lymphocyte infusion (DLI) or second HSCT.   
Indications for HSCT 
Allogeneic HSCT has a very potent antitumor activity, but also treatment related morbid-
ity and mortality. Indications for HSCT result from weighing the antitumor activity vs. 
treatment related mortality. This may differ from patient to patient and disease. One im-
portant factor is the patient´s age. HSCT indicated in adults might not be appropriate in 
children. The most frequent indications in adults are leukemias with high risk of relapse; 
malignant diseases without curative treatment alternatives; irreversible bone marrow 
failure syndromes; genetic disorders of blood cells such as thalassemia or sickle cell 
anemia. The mechanisms underlying autologous HSCT involve the dose response con-
cept without immunological reactions and these are therefore associated with low mor-
tality. Typical indications for autologous HSCT are plasma cell disorders and lympho-
mas in adults.  
HSCT in Children. 
Malignant diseases in children and adolescents have different incidence and biological 
characteristics than in adults.11,12 Childhood cancer amounts for 1% of all new cancer 
diagnosis in the USA13 and has a different origin. Cancers of embryonal origin such as 
Neuroblastoma or rhabdomyosarcoma are diseases typically rare in adults but frequent 
in children.13,11 Acute lymphocytic leukaemia has its peak incidence during childhood14 
and is the most frequent cancer in children under the age of 15 (26%). Brain and central 
nervous system tumours (21%) and Neuroblastoma (7%) are also frequent malignan-
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cies in children. Between the age of 15 to 19 Hodgkin Lymphoma (15%), thyroid carci-
noma (11%) and brain/central nervous system tumours (10%) are the most frequent 
malignant diseases according to an US based evaluation.13 
It is not surprising that indications for HSCT in children can differ considerably from 
those in adults. In addition, high cure rates with chemotherapy, the possibility to use 
intense and high dose regimens without bone marrow rescue and the lower relapse 
rates are also important determinants contributing to the indications for HSCT in chil-
dren. However, no detailed information and comparison to adults has been available to 
date and this was the main motivation for this evaluation.  
In this study we retrospectively assessed the incidence and outcome of HSCT in malig-
nant and non-malignant diseases in children and adolescents who were diagnosed at 
one center between the years 1999 and 2011 and were transplanted at different paedi-
atric centers. Furthermore, our analysis included the evaluation of multiple HSCT for 
relapses and therapy related malignancies, of risk factors for outcome and possible dif-
ferences between the use of autologous and allogeneic HSCT. Finally, questions relat-
ed to the source of stem cells for HSCT and center effect (paediatric and combined 




-How frequent are the indications for HSCT in pediatric hematological and onco-
logical patients? 
-Which are the most frequent indications for HSCT in pediatric patients? 
-How are the HSCT distributed among type (autologous or allogeneic), source 
(bone marrow or peripheral blood), donor type for allogeneic (related, unrelated) 
and degree of compatibility (matched mismatched or haploidentical).  
-How significant is the rejection rate? 
-How was the outcome of autologous and allogeneic HSCT and which risk fac-
tors were found?  
-Does the EBMT risk score apply also to children? 
-Are multiple HSCT feasible? 
























Indication and incidence of HSCT in children and adolescents were analyzed in a He-
matology and Medical Oncology Department of a University Hospital during a 12 year 
period. Only a minority of the 483 patients (predominantly those with very high risk dis-
ease) were treated with single/multiple autologous or with matched/mismatched alloge-
neic HSCT in different HSCT centers. Despite a high proportion of advanced diseases 
and high risk HSCT, outcome resulted in a favorable 63% OS at 10 years with low non-
relapse mortality. The major obstacle remains the high relapse rate, which should be 
intensively addressed in upcoming protocols.  
Only 8.5% of patients with hematological or oncological diseases received HSCT. The 
most frequent disease-specific indication was acute myeloid leukemia (33%) followed 
by myelodysplastic syndrome (MDS; 30%), Ewing Sarcoma (27%) and aplastic ane-
mia/Fanconi (27%). Less frequent was the indication for patients with acute lympho-
blastic leukemia (10%), NHL (10%) and Hodgkin lymphomas (13%). To our knowledge, 
this is the first population-based evaluation of indications and frequency in pediatric dis-
eases and clearly adds additional important information to the European adult/pediatric 
HSCT survey,15 which reports HSCT in children to account for 11% of the total HSCT 
performed in Europe. This figure was estimated to be 14% in a US population.16 
The frequency of autologous HSCT as compared to allogeneic HSCT differs in children 
compared to adults. While in adults more autologous than allogeneic HSCT were re-
ported in Europe (58%)15 and worldwide (54%),6 in our pediatric population more al-
logeneic HSCT (63%) than autologous were noted. This is comparable to the European 




ed from allogeneic donors in 37 centers of nine East European countries 17. Differences 
in health systems and economic background may be responsible for this effect. 
Acute leukemias, MDS, aplastic anemia/Fanconi and NHL were the most frequent indi-
cations for allogeneic HSCT. In comparison to the European pediatric survey data15 the 
proportion of patients with acute leukemias was higher in our population (62% vs. 40%, 
respectively). The same is true for MDS (12% vs. 8% respectively) and NHL (8% vs. 
2%, respectively). While other indications were similar (AA, 15 vs 12%, respectively), no 
patients with thalassemia, sickle cell anemia or autoimmune diseases were transplanted 
in our center. The pattern of indications in adults in Europe is similar, with a predomi-
nance of acute leukemia (50%), followed by MDS (15%) and aplastic anemia/Fanconi 
(6%). Furthermore, a high proportion of patients (64%) were in advanced phase of their 
disease (aplastic anemia/Fanconi and MDS excluded).  
While neuroblastoma was the most frequent indication for autologous HSCT both in our 
center and in the European survey (33% vs. 35%, respectively), clear differences be-
tween our study and the European survey were observed in solid tumors (6% vs. 31%, 
respectively), Ewing sarcoma and Hodgkin disease (HD; each 27% vs. 11%, respective-
ly). Strikingly, none of the patients was in CR at the time of treatment, autologous HSCT 
being used to reach CR. Center effects are a potential reason for this difference. 
The pediatric indications for autologous HSCT were clearly different from those of 
adults, where autologous transplants were performed for PCD 47%, NHL 30%; HD 11% 
due to the different age distribution of diseases15. 
In comparison to allogeneic HSCT in adults, 50% of the HSCT in children were per-




ropean level with 34% of pediatric and 13% of adult patients receiving bone marrow 
grafts. Increased incidence of chronic GvHD in adults after peripheral blood stem cell 
transplantation (PBSCT) as compared to bone marrow might be the driving force for 
these differences. In contrast, PBSCT was the most frequent source used in autologous 
HSCT in our population (100%) and in Europe (92,7%) in children and adults. 
More unrelated compared to related donors were performed in our center (62%) than in 
the European pediatric/adult survey (48%) or in adults (54%)15. In addition, far more 
mismatch combinations were transplanted in our center (41%) than in the European 
centers for pediatric (23%) and for adult patients (17%). Despite the high proportion of 
unrelated and mismatched HSCT, rejection rate was only 4%. 
Despite the high proportion of advanced disease and the use of non-identical and unre-
lated donors overall survival (OS) was 63% and EFS 57% after allogeneic HSCT with a 
plateau after two years, with a NRM of 4% and a relapse incidence of 39%. The NRM 
observed in our cohort compares favorably to the one reported by Miano of 21% at 2 
years18. No relapse and no NRM were observed two years after HSCT. 
After autologous HSCT the figures were similar with 63% OS and EFS 42% at 10 years, 
with a plateau being reached only after 7 years. The relapse incidence was 44% and 
the NRM after autologous HSCT was higher (13%) than after allogeneic HSCT, but this 
figure includes death after maintenance therapy. In the report of Miano18 NRM amount-
ed 9% at 2 years, but information on maintenance was not provided. 
The risk factors for outcome were disease stage and EBMT risk score. To our 
knowledge this is the first time that the EBMT risk score was evaluated in children and it 




trend. Interestingly, NRM was favorable in acute leukemia in comparison to the patients 
with other diseases. The same is true for transplant in 2006 and later, but there was a 
trend to statistical significance for higher RI in acute leukemia than in other malignan-
cies. No center effect was seen to affect outcome between pediatric and combined 
adults/pediatric centers with JACIE accreditation. 
Our analysis shows the feasibility of second and third HSCT with an OS of 33%, which 
compares favorably to Bajwa et al19, who reported OS of 16% in hematological disease 
and is similar to the OS of 31% reported by Oda et al20 for children with AML after a se-




Relapse risk reduction remains the major aim and should be addressed in future proto-
cols. This may be accomplished by using minimal residual disease (MRD) as an indica-
tion for transplant but also to tailor immunosuppression after HSCT. Including epigenetic 
therapy after HSCT might be another way to reduce relapse after HSCT in high risk pa-
tients. More efficient and selective antitumor therapy before HSCT might be another 
approach to pursue. Furthermore quantification and surveillance on morbidity on long 
term follow-up remains an important issue. Extensive analyses on morbidity especially 
in children are lacking. Fertility is becoming an important issue and may be avoided with 
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Hematopoietic stem cell transplantation (HSCT) has been successfully developed over 
decades and has recently reached one million procedures worldwide. Today, HSCT is 
the therapy of choice for many malignancies and non-malignant hematological diseas-
es. Allogeneic HSCT delivers high dose chemotherapy in combination with an immuno-
logical reaction of donor immune cells against the tumor, called Graft-versus Tumor 
(GvT) effect. In contrast, autologous HSCT enables the use of high-dose chemotherapy 
followed by stem cell support in chemo-sensitive diseases. In adults, autologous trans-
plants are frequently performed for plasma cell disorders, non-Hodgkin Lymphoma and 
Hodgkin disease.  
The information concerning HSCT in children remains scarce, with European surveys 
regarding indication being published only recently and outcome still pending. The better 
response to standard chemotherapy in children, the possibility to apply more intensive 
chemotherapy cycles and the low relapse rate are reasons for considerable differences 





Patients and Methods: 
Indication and incidence of HSCT in children and adolescents were analyzed in a He-
matology and Medical Oncology Department of a University Hospital during a 12 year 
period.  
Results: 
Only a minority (8.5%) of the 483 patients and predominantly those with very high risk 
disease were treated with single/multiple autologous or with matched/mismatched al-
logeneic HSCT in different national HSCT centers. In contrast to adults, allogeneic 
HSCT was used more often than autologous transplantation. Leukemias and myelodys-
plastic syndrome were treated mainly with allogeneic HSCT and neuroblastoma, Ewing 
sarcoma and Hodgkin disease with autologous HSCT. Especially the indication for au-
tologous HSCT differed between children/adolescents and adults (e.g. neuroblastoma in 
children, plasma cell disorders and NHL in adults). 
Despite a high proportion of advanced diseases and high risk HSCT, outcome resulted 
in favorable 63% OS at 10 years for both allogeneic and autologous HSCT.  Non-
relapse mortality was low with 4% for allogeneic and 13% for autologous HSCT, but 
relapse rate was high with 39% and 44% for allogeneic and autologous respectively. 
Relapse was observed up to 2 years following allogeneic and up to seven years after 
autologous HSCT. Only one graft rejection with autologous recovery was observed in 
one patient with severe aplastic anemia. Second transplantations in children had a long-





Detailed answers to the research questions: 
How frequent are the indications for HSCT in our pediatric hematological and on-
cological patients? 
Only 8.5% of our pediatric patients with hematological and oncological diseases re-
ceived HSCT. 
Which are the most frequent indications for HSCT in pediatric patients  
Acute leukemias, MDS, aplastic anemia/Fanconi and NHL were the most frequent indi-
cations for allogeneic HSCT. Neuroblastoma, Ewing sarcoma and Morbus Hodgkin 
were the most frequent indications for autologous HSCT. 
 
How are HSCT distributed among type (autologous or allogeneic), source (bone 
marrow or peripheral blood), donor type (related, unrelated) and compatibility 
(matched, mismatched or haploidentical).  
There were more allogeneic (63%) transplanted patients than autologous. Bone marrow 
was the source in 50% of allogeneic HSCT in children. More unrelated than related do-
nors were used in our center (62%). A high number of mismatches were performed in 
our cohort compared to the rest of Europe (41%). 
 
What is the rejection rate?  
Despite a high proportion of unrelated and mismatched HSCT, rejection was only 4%. 
 
How was the outcome of autologous and allogeneic HSCT including evaluation of 
risk factors?   
Outcome resulted in favorable 63% OS at 10 years for both allogeneic and autologous.  
Non-relapse mortality was low with 4% for allogeneic and 13% for autologous HSCT. 
Relapse rate was high with 39% and 44% for allogeneic and autologous, respectively. 
Relapse was observed up to 2 years in allogeneic and more than seven years in autol-
ogous. Risk factors for outcome were diseases stage and EBMT risk score. Acute leu-
kemias had a better non-relapse mortality than non-leukemias and NRM improved in 
the period after 2006. 
 
Does the EBMT risk score apply also to children?  
EBMT risk score is a predictor for outcome also in children. 
 
Are multiple HSCTs feasible?  
Our analysis shows the feasibility of second and third HSCT in pediatric patients. 
 
Is there a center effect after HSCT for children?  
No center effect could be detected. 
Discussion: 
This analysis evaluates the incidence and frequency of HSCT in children and compares 




unfavorable diseases and high transplant risk, outcome is favorable with low NRM and 
compares favorably with disease-specific outcome of studies and results from adults. 
Relapse of the disease is still a major problem, even if second and third HSCT are fea-
sible and an option for treating relapses following HSCT. Steps must be taken to tackle 
the recurring disease by selecting for more effective therapy regimens. Risk factors 
should be used to influence future treatment decisions and provide guidance in the rare 
setting of children with hematological and oncological diseases in need for HSCT. Alt-
hough the number of patients assessed in our study is small, we could show a favorable 
outcome of autologous and allogeneic transplantation in children with specific diseases, 
and assess different risk factors despite the high proportion of mismatched donors. Pe-
diatric outcome registries are needed to analyze larger patient cohorts and confirm the 
results observed in this study. The messages are unique, considering that experiences 
reported here are across disease-specific clinical studies or outside prospective clinical 
studies. Patients not qualifying for currently active clinical studies (e.g. relapse) or 
where clinical studies were unavailable are included. This is to our knowledge the first 
publication showing a center-based population treated at different transplant centers 
and reporting outcome. The analysis closes a gap regarding information on indication, 
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Die hämatopoetische Stammzelltransplantation (HSCT) wurde über Jahrzehnte entwi-
ckelt und hat kürzlich die Zahl von einer Million durchgeführter Transplantationen welt-
weit überschritten. Die Stammzelltransplantation ist heute die Therapie der Wahl für 
viele maligne und nicht maligne hämatologische Erkrankungen. Die allogene Stamm-
zelltransplantation vereint eine Hochdosis Chemotherapie mit einer immunologisch 
vermittelten Reaktion durch immunkompetente Spenderzellen gegen Tumorzellen, auch 
bekannt als Transplantat- gegen-Tumor-Reaktion. Im Gegensatz dazu erlaubt die auto-
loge HSCT die Gabe einer ultrahohen Chemotherapie durch Stammzellreinfusion in 
Chemotherapie-sensitiven Erkrankungen. Bei erwachsenen Patienten wird die autologe 
HSCT vor allem bei malignen Plasmazell-Erkrankungen (z.B. Multiples Myelom), non-
Hodgkin Lymphomen (NHL) und Hodgkin Erkrankungen (HD) durchgeführt.  
Spärlich ist die Studienlage bei Kindern, wo nur kürzlich ein Überblick über europäische 




Besseres Ansprechen auf Standard Chemotherapie bei Kindern und Jugendlichen, die 
Möglichkeit höhere Dosen an Chemotherapie zu verabreichen und eine niedrige Rezidiv 
Rate bewirken deutliche Unterschiede in der Häufigkeit (nur 10% aller HSCT werden 
bei Kindern durchgeführt) und Indikation zwischen pädiatrischen und erwachsenen Pa-
tienten.  
Methoden: 
In dieser Arbeit werden die an der Universität Leipzig in einem zwölf Jahres Zeitraum 
diagnostizierten 483 Patienten mit hämatologischen und onkologischen Erkrankungen 
bezüglich HSCT-Häufigkeit und Indikationen analysiert.  
Ergebnisse: 
Nur eine Minderheit der 483 Patienten (8.5%) und vorwiegend diese mit Hochrisiko Er-
krankungen wurden mit einfacher/mehrfacher autologer oder identen/teilweise identer 
allogener HSCT an verschiedenen nationalen Transplantations-Zentren transplantiert. 
Im Gegensatz zu Erwachsenen wurden Kinder und Jugendliche häufiger allogen (63%) 
als autolog HSCT behandelt. Patienten mit Leukämien und myelodysplastischem Syn-
drom wurden vorwiegend mit der allogenen HSCT behandelt und das Neuroblastom, 
das Ewing Sarkom und das Hodgkin Lymphom mit einer autologen HSCT. Insbesonde-
re die Indikation für autologe HSCT war zwischen Kindern/Jugendlichen und Erwachse-
nen unterschiedlich (z.B. das Neuroblastom bei Kindern und maligne Plasmazell-
Erkrankung und non-Hodgkin Lymphom bei Erwachsenen). 
Trotz eines hohen Anteils von hoch Risiko HSCT, waren gute Ergebnisse mit 63% 
Überleben nach 10 Jahren für sowohl allogene als auch autologe HSCT erzielbar. 




plantationen sehr gering, die Rezidiv Häufigkeit jedoch bei 39% nach allogener und 
44% nach autologer HSCT zu beobachten. Das Rezidiv trat maximal bis zu zwei Jahre 
nach der allogenen und bis zu sieben Jahre nach der autologen HSCT auf. Lediglich bei 
einem Patienten war eine Transplantatabstoßung mit autologer Rekonstitution in einem 
Patienten mit schwerer aplastischer Anämie aufgetreten. Zweit-Transplantationen bei 
Kindern hatten ein Langzeitüberleben von 33% und  Dritttransplantationen waren ohne 
Mortalität möglich. 
Detaillierte Antworten zu den Thesen. 
-Wie häufig ist die Inzidenz von hämatopoietischen Stammzelltransplantationen 
(HSCT) in Kindern und Jugendlichen mit hämatologischen und onkologischen 
Erkrankungen diagnostiziert an der Universität Leipzig. 
8.5% der Kinder und Jugendlichen erhielten eine HSCT.  
-Welches sind die häufigeren Indikationen für eine HSCT in Kindern und Jugend-
lichen? 
 Akute Leukämien, MDS, aplastische Anämie/Fanconi Anämie und Non-Hodgkin Lym-
phome sind die häufigsten Indikationen für eine allogene HSCT. Neuroblastom, Ewing 
Sarkom und Morbus Hodgkin sind die häufigsten für die autologe HSCT in Kindern 
und Jugendlichen.  
-Wie verteilen sich die HSCTs nach Art (autolog oder allogen), Ressource (Kno-
chenmark oder Periphere Blut-Stammzellen), für allogene HSCT (verwandt, un-
verwandt) und Grad der Kompatibilität (ident und teilweise ident oder haploi-
dent).  
Mehr Patienten wurden allogen transplantiert (63%) und weniger autolog. Knochen-
mark wurde in 50% der allogenen HSCT in Kindern und Jugendlichen verwendet. Es 
wurden mehr unverwandte (62%) als verwandte Spender verwendet. Es wurden häu-
figer (41%) teilweise idente Spender verwendet als in Europa üblich.  
-Wie hoch ist die Abstoßungsrate?  
Trotz der hohen Zahl an unverwandten und teilweise identen Spendern lag die Absto-
ßungsrate lediglich bei 4%.  
-Überleben und Wiederkehr der Erkrankung bei autologen und allogenen HSCT 
mit Berücksichtigung von Risikofaktoren.  
Risikofaktoren waren Stadium der Erkrankung und der EBMT Risiko-Score. Nicht mit 
der Wiederkehr der Erkrankung assoziierte Mortalität war geringer in akuten Leukä-
mien im Vergleich zu den anderen malignen Erkrankungen und verbesserte sich in der 




-Kann man den EBMT Risiko-Score auch in Kindern und Jugendlichen anwen-
den?  
Der EBMT Risiko-Score war auch prädiktiv in Kindern und Jugendlichen. 
-Sind Mehrfachtransplantationen in Kindern machbar?  
Unsere Analyse zeigt die Machbarkeit von Zweit- und Dritt-Transplantationen.  
-Gibt es einen Zentrums-Effekt bei der Kindertransplantation und können Kinder 
in einem kombinierten Kinder-und-Erwachsenen Zentrum transplantiert werden.  
Es gibt keinen Zentrums-Effekt. 
 
Diskussion: 
Diese Arbeit untersucht die Inzidenz und Frequenz von Kinder und Jugendlich- Trans-
plantationen im Vergleich zu den europaweiten Aktivitäten bei Kindern/Jugendlichen 
und Erwachsenen.  
Trotz einer hohen Frequenz von Hochrisiko Erkrankungen und hohem Transplantations- 
Risiko, wurden günstige Überlebenskurven mit niedriger, nicht rezidiv bedingter Mortali-
tät nachgewiesen, und günstigere Verläufe als in Erwachsenen gezeigt.  
Das Rezidiv der Erkrankung bleibt immer noch das Hauptproblem, auch wenn Zweit- 
und Dritt-Transplantation möglich sind und eine Behandlungsmöglichkeit des Rezidivs 
darstellen. Schritte müssen unternommen werden um die Rezidiv Rate zu senken, mög-
licherweise durch Auswahl effizienterer Therapie-Schemata. Die beschriebenen Risiko-
faktoren sollten angewendet werden um zukünftige Behandlungsentscheidungen zu 
beeinflussen und helfen Therapieentscheidungen bei seltenen Erkrankungen von Kin-
dern mit hämatologischen und onkologischen Erkrankungen zu fällen.  
Obwohl die Patientenzahl dieser Analyse klein ist, konnten wir ein günstiges Überleben 
nach autologer und allogener HSCT bei Kindern mit spezifischen Erkrankungen zeigen, 




Spendern identifizieren. Pädiatrische Register werden gebraucht um größere Patienten-
Kohorten zu analysieren und um die Ergebnisse dieser Studie zu bestätigen.  
Die Aussagen dieser Studie sind einzigartig, wenn man bedenkt, dass die hier präsen-
tierten Erfahrungen, krankheitsspezifische Studien übergreifen oder außerhalb prospek-
tiver klinischer Studien gesammelt wurden. Inkludiert wurden auch Patienten die wegen 
vorhandener Ausschluss-Kriterien nicht in aktuelle klinische Studien rekrutiert werden 
konnten (z.B. bei Rezidiv) oder bei Fehlen einer passenden Studie.  
Dies ist nach unserem Wissen die erste Analyse einer zentrumsbasierten Population, 
die an verschiedenen Orten transplantiert wurde und Ergebnisse dokumentiert. Die 
Analyse schließt eine Lücke in Bezug auf Informationen zu Indikation, Häufigkeit und 
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